Close Menu

NEW YORK – Horizon Discovery said on Tuesday that it has granted two commercial licenses for its CHOSource platform to biotechnology company Sanyou Biopharmaceuticals.

Sanyou will use Horizon's gene-edited Glutamine Synthetase knockout Chinese Hamster Ovary (CHO) K1 cell line for the development of preclinical antibody drug projects and to support the clinical development and commercialization of its customers' human biotherapeutic products. Sanyou will also offer CHOSource through its contract research services, Horizon added.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Researchers are developing a breath test to determine how severe patients' methylmalonic acidemia disease is, FierceBiotech reports.

NPR reports that vaccine developers are working on SARS-CoV-2 vaccines that are easier to store or administer than the current crop.

Reuters reports that France is to recommend that people under 55 who received one dose of AstraZeneca's SARS-CoV-2 vaccine receive a different vaccine for their second dose.